- Previous Close
0.5460 - Open
0.5570 - Bid --
- Ask --
- Day's Range
0.5327 - 0.5905 - 52 Week Range
0.2020 - 1.6000 - Volume
2,229,772 - Avg. Volume
1,018,810 - Market Cap (intraday)
56.932M - Beta (5Y Monthly) 2.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.25
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
unicycive.comRecent News: UNCY
View MorePerformance Overview: UNCY
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UNCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UNCY
View MoreValuation Measures
Market Cap
56.67M
Enterprise Value
25.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.85%
Return on Equity (ttm)
-147.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.1M
Diluted EPS (ttm)
-0.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
32.35M
Total Debt/Equity (mrq)
2.90%
Levered Free Cash Flow (ttm)
-22.03M